Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,...
Reexamination Certificate
2007-12-25
2007-12-25
Gambel, Phillip (Department: 1644)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
C424S141100, C424S143100, C424S144100, C424S154100, C530S387100, C530S387900, C530S388100, C530S388200, C530S388220, C530S388750
Reexamination Certificate
active
10461000
ABSTRACT:
The invention identifies the CTLA4 receptor as a ligand for the B7 antigen. The complete amino acid sequence encoding human CTLA4 receptor gene is provided. Methods are provided for expressing CTLA4 as an immunoglobulin fusion protein, for preparing hybrid CTLA4 fusion proteins, and for using the soluble fusion proteins, fragments and derivatives thereof, including monoclonal antibodies reactive with B7 and CTLA4, to regulate T cell interactions and immune responses mediated by such interactions.
REFERENCES:
patent: 4399216 (1983-08-01), Axel
patent: 4683195 (1987-07-01), Mullis et al.
patent: 4683202 (1987-07-01), Mullis
patent: 5521288 (1996-05-01), Linsley et al.
patent: 5580756 (1996-12-01), Linsley et al.
patent: 5883223 (1999-03-01), Gray
patent: 5916560 (1999-06-01), Larsen et al.
patent: 5968510 (1999-10-01), Linsley et al.
patent: 6352694 (2002-03-01), June et al.
patent: 6444792 (2002-09-01), Gray et al.
patent: 6534055 (2003-03-01), June et al.
patent: 6641809 (2003-11-01), Linsley et al.
patent: 6685941 (2004-02-01), Thompson et al.
patent: 6719972 (2004-04-01), Gribben et al.
patent: 6750334 (2004-06-01), Gray et al.
patent: 6830937 (2004-12-01), Linsley et al.
patent: 2001/0053361 (2001-12-01), Thompson et al.
patent: 2002/0031510 (2002-03-01), Larsen et al.
patent: 2002/0039577 (2002-04-01), Townsend et al.
patent: 2002/0115214 (2002-08-01), June et al.
patent: 2002/0182211 (2002-12-01), Peach et al.
patent: 2003/0007968 (2003-01-01), Larsen et al.
patent: 2003/0022836 (2003-01-01), Larsen et al.
patent: 2003/0083246 (2003-05-01), Cohen et al.
patent: 2003/0219863 (2003-11-01), Peach et al.
patent: 2004/0014171 (2004-01-01), Peach et al.
patent: 2004/0022787 (2004-02-01), Cohen et al.
patent: 0 613 944 (1994-09-01), None
patent: 0 682 039 (1995-11-01), None
patent: WO 93/00431 (1993-01-01), None
patent: WO93/19767 (1993-10-01), None
patent: WO94/28912 (1994-12-01), None
patent: WO95/33770 (1995-12-01), None
patent: WO97/28267 (1997-08-01), None
patent: WO2004/058800 (2004-07-01), None
patent: WO2004/058944 (2004-07-01), None
patent: WO2005/016266 (2005-02-01), None
Blazar et al., J. Immunol., 1996, 157: 3250-3259.
Leach et al., 1996, Science, 271: 1734-1736.
Kwon et al., 1999, PNAS, 96: 15074-15079.
McCoy et al., 1997, J. Exp. Med., 186: 183-187.
Janeway, “Approaching The Asymptote? Evolution And Revolution Immunology,”Cold Spring Harbor Symp. Quant. Biol., 1989, LIV:1-13. (Exhibit 4).
Shaw and Shimuzu, “Two Molecular Pathways Of Human T Cell,”Current Opinion in Immunology, 1988, 1:92-97. (Exhibit 5).
Hemler, “Adhesive Protein Receptors On Hematopoietic Cells,”Immunology Today, 1988, 9:109-113. (Exhibit 6).
Kakiuchi et al., “B Cells as Antigen-Presenting Cells: The Requirement for B Cell Activation,”J. Immunol., 1983, 131:109-114. (Exhibit 7).
Krieger et al., “Antigen Presentation Bye Splenic B Cells: Resting B Cells are Ineffective, Whereas Activated B Cells Are Effective Accesorry Cells For T Cell Responses,”J. Immunol., 1988, 135:2937-2945. (Exhibit 8).
Mckenzie, “Alloantogin Presentation By B Cells—Requirement for IL-1 And IL-6,”J Immunol, 1988, 141:2908-2911. (Exhibit 9).
Hawrylowicz and Unaue, “Regulation of Antigen-Presentation-I IFN-γInduces Antigen- Presenting Properties On B Cells,”J. Immunol, 1988, 141:4803-4088. (Exhibit 10).
Springer et al., “The Lymphocyte Function-Associated LFA-1, CD2, and LFA-3 Molecules: Cell Adhesion Receptors Of The Immune System,”A. Rev. Immunol.1987, 5:223-252. (Exhibit 11).
Dinarello and Mier, “Current Concepts—Lymphokines,”New Engl. Jour. Med., 1987, 317:940-945. (Exhibit 12).
Weiss et al., “The Role Of The T3/Antigen Receptor Complex In T-Cell Activation,”Ann. Rev. Immunol, 1986, 4:593-619. (Exhibit 13).
McMichael, Ed., “Non-lineage, LFA-1 Family, And Leucocyte Common Antigens: New And Previously Defined Clusters,”Leukocyte Typing III, Oxford Univ. Press, Oxford, UK, 1987. (Exhibit 14).
Moingeon et al., “CD2-Mediated Adhesion Facilitates T Lymphocyte Antigen Recognition Function”Nature, 1988, 339:312-314. (Exhibit 15).
Magkoba et al., ICAM-1 A Ligand For LFA-1-Dependent Adhesion Of B, T, And Myeloid Cells,Nature, 1988, 331:86-88. (Exhibit 16).
Staunton et al., “Functional Cloning Of ICAM-2, A Cell Adhesion Ligand For LFA-1 Homologous To ICAM-1,”Nature, 1989, 339:61-64. (Exhibit 17).
Norment et al., “Cell-Cell Adhesion Mediated By CD8 And MHC Class I Molecules,”Nature, 1988, 336:79-81. (Exhibit 18).
Doyle and Strominger, “Interaction Between CD4 And Class II MHC Molecules Mediates Cell Adhesion,”Nature, 1987, 330:256-259. (Exhibit 19).
Stoolman, “Adhesion Molecules Controlling Lymphocyte Migration,”Cell, 1989, 56:907-910. (Exhibit 20).
Brescher and Cohn, “A Theory Of Self-Nonself Discrimination,”Science, 1970, 169:1042-1049. (Exhibit 21).
Freeman et al., “B7, A New Member of the Ig Superfamily With Unique Expression on Activated and Neoplastic B Cells,”J. Immunol., 1989, 143(8):2714-2722. (Exhibit 22).
Freedman et al., “B7, A B Cell-Restricted Antigen That Identifies Preactivated B Cells,”J. Immunol., 1987, 138:3260-3267. (Exhibit 23).
Clark et al., “Polypeptides On Human B Lymphocytes Associated With Cell Activation,”Human Immunol., 1986, 16:100-113. (Exhibit 24).
Yokochi et al., “B Lymphoblast Antigen (BB1-) Expressed On Epstein-Barr Virus-Activated B Cells Blasts, B Lymphoblastoid Cell Lines, And Burkitt's Lymphomas,”J. Immunol., 1981, 128:823-827. (Exhibit 25).
Weiss, “Structure And Function Of The T Cell Antigen Receptor,”J. Clin Invest., 1990, 86:1015-1022. (Exhibit 26).
Allen, “Antigen Processing At The Molecular Level,”Immunol. Today, 1987, 8:270-273. (Exhibit 27).
Schwartz, “A Cell Culture Model For T Lymphocyte Clonal Anergy,”Science, 1990, 248:1349-1356. (Exhibit 28).
Weaver and Unanue, “The Costimulatory Function Of Antigen-Presenting Cells,”Immunol Today, 1990, 11:49-55. (Exhibit 29).
Arrufo and Seed, “Molecular Cloning Of A Cd28 cDNA By A High-Effeciency COS Cell Expression System,”Proc. Natl. Acad. Sci., 1987, 84:8573-8577. (Exhibit 30).
Damle et al., “Alloantigen-Specific Cytotoxic And Suppressor T Lymphocytes Are Derived From Phenotypically Distinct Precursors,”J. Immunol., 1983, 131:2296-2300. (Exhibit 31).
June et al., “T-Cell Proliferation involving The CD28 Pathway Is Associated With Cyclosporine-Resistant Interleukin 2 Gene Expression,”Mol. Cell. Biol., 1987, 7:4472-4481. (Exhibit 32).
Thomopson et al., “CD28 Activation Pathway Regulates The Production Of Multiple T-Cell- Derived Lymphocytes/Cytokines,”Proc. Natl. Acad. Sci. 1989, 86:1333-1337. (Exhibit 33).
Linsten et al., “Regulationn Of Lymphokine Messenger RNA Stability Bye A Surface-Mediated T Cell Activation Pathway,”Science, 1989, 244:339-343. (Exhibit 34).
Damle et al., “Monoclonal Antibody Analysis Of Human T Lymphocyte Subpopulations exhibiting Autologous Mixed Lymphocyte Reaction”Proc. Natl. Acad. Sci., 1981, 78:5096-5098. (Exhibit 35).
Lesslauer et al., “T90/44 (9.3 Antigen). A Cell Surface Molecule With A Function In Human T Cell Activation,”Eur. J. Immunol., 1986, 16:1289-1296. (Exhibit 36).
Linsley et al., “T-Cell Antigen CD28 Mediates Adhesion With B Cells By Interacting With Activation Antigen B/7BB-1,”Proc. Natl. Acad. Sci. USA, 1990, 87:5031-5035. (Exhibit 37).
Linsley et al., “Binding Of The B Cell Activation Antigen B7 To CD28 Costimulates T Cell Proliferation And Interleukin 2 mRNA Accumulation,”J. Exp. Med., 1991, 173:721-730. (Exhibit 38).
Kohno et al., “CD 28 Molecule As a Receptor-like Function For Accessory Signals In Cell-Mediated Augmentation Of IL-2 Production,”Cell.Immunol., 1990, 131:1-10. (Exhibit 39).
Brunet et al.,
Brady William
Damle Nitin K.
Ledbetter Jeffrey A.
Linsley Peter S.
Bristol--Myers Squibb Company
Bristol-Myers Squibb Company
Gambel Phillip
Mandel & Adriano
Ouspenski Ilia
LandOfFree
Methods for treating cancer and infectious disease by... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods for treating cancer and infectious disease by..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods for treating cancer and infectious disease by... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3876478